Six years have passed since the so-called “G1” rule and associated market withdrawal scheme were introduced for long-listed products (LLPs). As initially planned, a batch of LLPs saw their NHI price brought down to the generic levels for the first…
Chiesi Joins Japan Rare Disease Market, Shoots for 10 Billion Yen Sales by 2030
To read the full story
BUSINESS
- Takeda Seeks CIDP Nod for Immunoglobulin Hyqvia in Japan
August 9, 2024
- Japan Patented Drug Market Breaks 7 Trillion Yen in FY2023: IQVIA
August 9, 2024
- Hizentra Now Available in Prefilled Syringe Form in Japan: CSL
August 9, 2024
- Nobelpharma to Launch Hypozincemia Drug Zintus on August 20
August 9, 2024
- Pfizer Earns Japan Nod for JN.1-Adapted COVID Vaccine
August 9, 2024
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…